Capicua ()-rearranged sarcomas are an aggressive subset of undifferentiated round cell sarcomas. CIC::DUX4, the proto-typical CIC fusion oncoprotein is associated with rapid clinical progression and chemotherapy resistance leading to poor clinical outcomes. Recent studies have identified additional CIC fusions (CIC::NUTM1, CIC::FOXO4, and CIC::LEUTX) that largely retain CIC-binding specificity but leverage C-terminal binding partners (NUTM1, FOXO4, and LEUTX) to potentially activate transcriptional programs that drive oncogenesis. Moreover, the recent development of preclinical models to study CIC::DUX4 sarcoma have advanced our understanding of the underlying biological mechanisms and uncovered key dependencies that can be translated into rational therapies. In this review, we will highlight these recent advancements in -rearranged sarcoma biology with a vision for clinical translation to improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11176417 | PMC |
| http://dx.doi.org/10.3389/fcell.2024.1416697 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dermal CIC-Rearranged Sarcoma With Neuroendocrine Differentiation Mimicking Merkel Cell Carcinoma.
J Cutan Pathol
December 2024
SkinPath Solutions, Smyrna, Georgia, USA.
Capicua transcriptional repressor (CIC)-rearranged sarcoma (CRS) is a rare and recently described tumor that most commonly affects patients between 15 and 30 years of age. It is an undifferentiated round cell malignancy, with a disease defining CIC fusion, with double homeobox 4 (DUX4) being the most common partner. Here, we report a 77-year-old woman who presented with a cutaneous thigh mass with a clinical morphology suggesting Merkel cell carcinoma.
View Article and Find Full Text PDFCapicua transcriptional repressor (CIC)-rearranged sarcoma harboring fusion with renal involvement: a rare case report.
Transl Cancer Res
October 2024
Department of Oncology, Suzhou Ninth People's Hospital, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, China.
Background: Capicua transcriptional repressor (CIC)-rearranged sarcoma (CRS) is a rare and highly aggressive undifferentiated small round cell sarcoma (USRCS), which genetically displays a characteristic gene fusion between gene with other genes such as .
Case Description: We report a rare case with fusion. The 45-year-old male patient presented to our department with frequent dry cough and lumbar pain.
Dumbbell-Shaped capicua transcriptional repressor-rearranged sarcoma of lumbar spinal canal misdiagnosed as schwannoma: The imaging diagnostic clues.
Asian J Surg
September 2024
Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Mesenchymal Non-Meningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists.
AJNR Am J Neuroradiol
September 2024
(1) Department of Radiology, Mayo Clinic, Jacksonville, 4500 San Pablo Road, Jacksonville, FL 55902, USA (N.S, A.D, V.G, A.A), (2) Department of Nuclear Medicine, Sanjay Gandhi post graduate institute of medical science, Lucknow 226014, India, (MO), (3) University of Rochester, School of Medicine and Dentistry, Rochester NY 14620 (D.S), (4) Department of Radiology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55902, USA (G.B), (5) Department of Radiology,619 19th St S, Birmingham, AL 35294 (AS).
The World Health Organization Classification of Tumors of the Central Nervous System (WHO CNS5) significantly revised the terminology and diagnostic criteria of "mesenchymal non-meningothelial" tumors of CNS to better align with the classification of these soft tissue tumors outside the CNS. The CNS chapter only covers the entities with distinct histological or molecular characteristics that occur exclusively or primarily in the CNS. These tumors usually arise from the meninges and are rarely intraparenchymal in origin, mainly in the supratentorial compartment.
View Article and Find Full Text PDFCase report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab.
Front Oncol
July 2024
Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Article Synopsis
- Undifferentiated small round-cell sarcomas (uSRCSs) are a tricky type of cancer to diagnose and treat, with no specific treatments available for advanced cases.
- A 37-year-old woman with advanced uSRCS tried several treatments that didn't work, including chemotherapy and a combination of other drugs.
- Finally, she responded well to a new treatment combining surufatinib and camrelizumab after many earlier treatments failed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!